फेफड़ों का कैंसर (non-small cell)
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
कहाँ जाना है
इस trial के लिए 1 hospital भारत में मरीज़ ले रहा है।
रजिस्ट्री समरी (तकनीकी)
Tyrosine Kinase Inhibitors (TKIs) especially higher generation TKI have higher CNS penetration rates and have shown favorable response rates in brain metastases. Brain radiotherapy/surgery is the standard treatment in brain metastases especially symptomatic metastases, however, the role of local treatment especially in driver mutation-positive non-small cell lung cancer with asymptomatic brain metastases is being questioned given their potential side effects. No randomized trial has shown the superiority of early vs delayed cranial RT in asymptomatic BM of driver mutated NSCLC.
स्पॉन्सर: Tata Memorial Hospital
ClinicalTrials.gov पर NCT05236946
रजिस्ट्री में आखिरी अपडेट 10 Sep 2025 · हमने 20 Oct 2026 को पढ़ा